First-in-Human in Brazil in 2026: A Practical Timeline for Sponsors

Primary keyword: first-in-human trial Brazil timeline

Brazil is increasingly on the shortlist for early-stage clinical development because sponsors can combine a large patient base with growing regulatory clarity. A recent policy analysis argued that Lei 14.874 de 2024 created the basis for a more predictable environment and, for the first time, establishes timelines and greater regulatory clarity for clinical studies.

This article gives a practical, sponsor-side timeline for launching a first-in-human (FIH) study in Brazil in 2026—what to do first, what typically slows teams down, and how to sequence work so you do not lose weeks to preventable back-and-forth.

1) Define the “Brazil-ready” FIH package (Weeks 0–2)

Before any submission, align internal stakeholders on what “Brazil-ready” means. For most MedTech and biopharma sponsors, FIH readiness is not only a protocol question—it is also a documentation and site execution question.

• Protocol and IB alignment: Ensure endpoints, safety monitoring, and dose-escalation logic are consistent with your global plan.
• Country adaptations: Identify what must be localized or supplemented (consent language, site materials, labeling, and investigator documentation).
• Feasibility assumptions: Confirm whether required imaging, lab, or procedural capabilities exist at target sites.

Internal best practice: Create a single “FIH Brazil master checklist” with owners and due dates. Treat it as a deliverable, not an afterthought.

2) Select sites for speed, not just prestige (Weeks 1–4)

In FIH, startup speed is highly correlated with site readiness. Sponsors often choose sites based on reputation, then discover contracting and operational realities late.

• Prioritize operational maturity: Look for sites with dedicated research staff, established ethics processes, and experience with sponsor audits.
• Validate recruitment pathways: Treatment-naive populations can be an advantage, but referral networks still matter.
• Assess import and handling constraints: If your study uses temperature-sensitive materials, confirm storage and chain-of-custody procedures early.

3) Build a parallel workstream plan (Weeks 2–6)

The most common timeline mistake is running tasks sequentially that can be executed in parallel. Even when formal review clocks improve, sequential execution can erase the benefit.

To compress time, run these workstreams at the same time:

• Regulatory dossier preparation (quality, safety documentation, and trial authorization package)
• Ethics submission package (site-specific documents and consent)
• Contracts and budgets (CTA, indemnities, payment schedules, and monitoring model)
• Supply and logistics readiness (import planning, labeling, storage validation, and back-up scenarios)

Even when legal reforms aim to improve predictability, sponsors still need coordinated execution across stakeholders to realize those gains.

4) Anticipate “hidden” startup time: contracts, import, and training (Weeks 4–10)

Even when review timelines are favorable, sponsors can lose time after approvals due to operational bottlenecks:

• Contract negotiation cycles: Build buffer time for legal review, redlines, and institutional sign-off.
• Import and release: If your investigational product or device must be imported, confirm lead times and documentation requirements early.
• Site initiation and training: FIH trials require strict adherence to safety procedures; schedule training sessions while approvals are in progress.

Practical tip: Maintain a “go-live readiness dashboard” that tracks contract status, shipment readiness, and training completion. This prevents surprises when the green light arrives.

5) A sponsor-friendly 2026 FIH timeline (example)

Every program is different, but a realistic planning template looks like this:

• Weeks 0–2: Brazil-ready protocol package, checklist, and internal alignment
• Weeks 1–4: Site selection, feasibility, and early budget/CTA drafts
• Weeks 2–6: Parallel dossier + ethics package finalization
• Weeks 4–10: Contracts, import planning, training, and vendor setup
• Weeks 10–14: Final site activation steps and first-patient readiness

If you are aiming for speed, measure time-to-ready as rigorously as you measure time-to-approval. In many FIH programs, the fastest sponsors are simply the ones that avoid rework.

FAQ: First-in-human trial Brazil timeline

• How long does it take to start a first-in-human trial in Brazil?
  Timelines vary by protocol complexity and site readiness, but sponsors should plan for parallel regulatory and ethics pathways, early document localization, and realistic contracting and import lead times.
• What is the biggest cause of FIH delays in Brazil?
  In practice, delays often come from incomplete documentation, late site selection, and underestimated startup logistics (contracts, import permits, and investigational product readiness), not just the formal review clock.
• Can Brazil FIH data support US or EU submissions?
  Yes, when the trial is designed to international GCP standards and endpoints align with your global regulatory strategy, Brazilian data can be part of a broader evidence package.

Need help planning an FIH startup in Brazil or across Latin America? bioaccess® supports sponsors with country startup planning, site activation, and operational execution—without exposing confidential details publicly.